LPS is an important component of the Gram-negative bacteria cell wall. It activates monocytes and induces multiple host immune and inflammatory responses. Interestingly, in spite of inducing host-inflammatory responses, LPS also protects monocyte-derived macrophages from infection by HIV-1. In this report, we have shown that LPS treatment of human monocyte-derived macrophages markedly suppressed HIV-1 replication, even on addition to infected cells 24 h after infection. Inhibition of HIV-1 replication was associated with PKCdependent induction of HO-1, a cytoprotective enzyme known to catabolize heme. Pretreatment with the PKC inhibitor Go 6976 not only substantially inhibited LPSmediated induction of HO-1 but also attenuated LPSinduced suppression of HIV replication. Significant reduction of HIV replication by inhibitors of JNK, NF-B, and PI3K was independent of a LPS-mediated anti-HIV effect. Specificity of HO-1 was confirmed by substantial reversal of LPS-induced viral replication by pretreatment of cells with SnPP IX, an inhibitor of HO-1 enzyme activity. These results demonstrate a previously undefined function of HO-1 as a host defense mechanism in LPS-mediated inhibition of HIV-1 replication.
Introduction
The cells of the monocyte/macrophage lineage are a major reservoir for HIV-1 in vivo and play a key role in the pathogenesis of HIV-1 disease. These cells serve as viral reservoirs in infected tissues and facilitate the transmission of virus to target cells, causing the persistence and spread of the virus. Peripheral blood monocytes that are latently infected in vivo can be activated by a number of agents to produce large quantities of virus [1] . HIV-1 replication is dependent on the host transcriptional machinery and is regulated closely by a complex pathway of proinflammatory cytokines and host factors. Many of these factors, including cytokines and growth factors, modulate HIV-1 expression. Some of these host factors are known to activate NF-B, which in turn, can induce long-terminal repeatdirected gene expression further. For example, TNF-␣ secreted by infected cells is known to up-regulate HIV-1 replication in an autocrine and paracrine manner [2] [3] [4] . Increased levels of various proinflammatory cytokines, such as TNF-␣, IL-1␤, IL-6, and IFN-␥, are reported in the serum and tissues of HIV-infected patients [5, 6] . These cytokines are apparently produced by host cells in response to infections and other antigenic stimuli preceding or in response to HIV infection [7, 8] .
In addition to the important role macrophages play in the pathogenesis of HIV-1 disease progression, these cells are actively involved in initiating immune responses to bacterial infections. Bacterial LPS, the major component of the outer membrane of Gram-negative bacteria, is known to activate multiple pathways in macrophages that are involved in immunoregulation and host defense. Activation of macrophages by LPS occurs when LPS binds to CD14, the LPS receptor, or the TLR complex TLR4 [9 -11] . The binding of LPS to the cellsurface receptors triggers the activation of several signal transduction pathways that leads to the phosphorylation of kinases, such as the IB kinases, PKC, PI3K, and MAPK family of proteins [12] [13] [14] [15] [16] . Phosphorylation of these families of proteins that transduce extracellular signals from the cell membrane to the nucleus leads to the activation of a number of different transcription factors such as NF-B and AP-1 [17] . These, in turn, cause the induction of proinflammatory cytokines, such as IL-1, IL-6, IL-8, TNF-␣, and IFN-␥, and chemokines [18] . In addition, LPS is known to trigger the expression of several protective host factors such as IL-10 and HO-1 to counteract the detrimental effects caused by proinflammatory cytokines [19 -22] .
Several studies have reported that pretreatment of monocytes/macrophages with LPS protects the cells from productive
Isolation and culture of monocyte-derived macrophages
Monocytes were isolated from PBMC of donors seronegative for HIV-1 and hepatitis B after leukophoresis and purified by countercurrent centrifugal elutriation [32] . Cell suspensions contained Ͼ95% monocytes by criteria of cell morphology on Wright-stained cytosmears, by granular peroxidase, and by nonspecific esterase. The cells were cultured for 5 days in DMEM, supplemented with 10% FBS, 20 g/ml gentamicin, and 1000 U/ml M-CSF. After 5 days, culture medium was removed completely, and the cells were washed three times with PBS and transferred to DMEM medium supplemented with 10% FBS and 20 g/ml gentamicin and cultured for an additional 2 days without M-CSF. All cell culture reagents were tested by Limulus lysate assay (Associates of Cape Cod, Cape Cod, MA, USA) for endotoxin contamination, and the levels were found to be Ͻ0.06 EU/ml.
Infection with HIV-1
Primary monocytes cultured for 5 days and pretreated with inhibitory compounds were infected with HIV-1 BaL , a monocytotropic HIV strain (Advanced Biotechnologies, Columbia, MD, USA), at a multiplicity of infection of 0.005 infectious virus particles/target cell. After a 2-h exposure, virus particles were removed, and fresh medium was added with appropriate additions of the inhibitory compounds and cultured at 37 o C until further use.
Treatment with inhibitors
Monocyte-derived macrophages were pretreated with 20 M MAPK inhibitors (PD 98059, SB 202190, and SB 203580), 20 M MAPK control compound (SB 202474), 20 mM JNK inhibitor (SP 600125), 20 M NF-B inhibitor (BAY 11-7082), 250 nM PKC inhibitor (Go6976), and 50 M PI3K inhibitor (LY294002), respectively, for 2 h. After 2 h, the monocyte-derived macrophages were treated with 100 ng/ml LPS for 24 h and infected with HIV-1. Cell viability was evaluated by Trypan blue dye exclusion and counting microscopically. No evidence of cell toxicity was detected at the concentrations of the inhibitors used (data not shown).
Treatment of monocytes with SnPP IX
Monocyte-derived macrophages were pretreated with 10 M SnPP for 2 h. After 2 h, the monocyte-derived macrophages were treated with 50 ng/ml LPS for 24 h and infected with HIV-1. No evidence of cell toxicity was detected at the concentration of SnPP used.
Quantitation of HIV-1 replication
Culture supernatants were assayed for HIV-p24 using a NEN/Dupont ELISA analysis kit (Perkin Elmer Life Sciences, Inc., Boston, MA, USA), according to the manufacturer's instructions. Assays were performed in triplicate.
Isolation of RNA from cells
Cultures of monocyte-derived macrophages were harvested and washed three times in ice-cold PBS. Total RNA was extracted using Qiagen RNAeasy columns (Qiagen, Inc., Valencia, CA, USA), according to the manufacturer's instructions. DNA was removed by DNase I (Qiagen, Inc.) digestion. RNA concentration and purity were determined by spectrophotometry at absorbance at 260 and 280 nm. RNA samples were aliquoted and stored at -70°C until further use.
RT
First-strand cDNA synthesis was carried out using the SuperScript TM firststrand synthesis system for RT-PCR (Invitrogen Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. The firststrand cDNA was synthesized using 0.5-2 g total cell RNA. The cDNA was analyzed subsequently by PCR reaction.
PCR
The cDNA products were analyzed by PCR using the AccuPrime TM Taq DNA polymerase system and HIV-1 env-specific PCR primers or human HO gene-specific PCR primers. The PCR products were separated on a 2% agarose gel using a Tris-borate buffer and visualized by ethidium bromide staining. To normalize for the amount of DNA or cDNA contained in each sample, primers were used to amplify a region of the GAPDH gene. Results were calculated as a ratio between the intensities of HIV-1 and GAPDH bands, quantitated by densitometric scanning.
Real-time PCR
Real-time fluorescence PCR was carried out using PCR Master Mix (Applied Biosystems), 200 nM forward and 200 nM reverse primers, and Taqman MGB probes (Applied Biosystems). Thermal cycling was performed for each gene (HIV-1, HO-1, and GAPDH) in triplicate on cDNA samples in a Micro-Amp Optical 96-well reaction plate (Applied Biosystems) using the ABI PRISM 7700 sequence detection system (Applied Biosystems). Amplification was carried out under the following conditions: 50°C for 2 min, 95°C for 10 min, and 45 cycles each of 95°C for 15 s and 60°C for 1 min. All data were captured using Sequence Detector software (Applied Biosystems). A standard curve was generated for the target HIV-1 and HO-1 genes and the endogenous control GAPDH gene. Each experimental sample was normalized relative to the endogenous control and the relative amount of target gene quantitated.
RESULTS

LPS inhibits infection of monocyte-derived macrophages
Monocyte-derived macrophages were cultured in the presence of LPS derived from S. typhosa and from five different strains of E. coli (026:B6, EH100, 055:B5, 0111:B4, and K-235) and infected with HIV-1. After 5 days postinfection, culture supernatants were harvested, and HIV-1 replication was quantitated by p24 ELISA. LPS treatment of monocytes suppressed HIV replication at Ͼ90% reduction in viral load, as compared with the untreated cells (Fig. 1) . The inhibitory effect of LPS on viral replication was evident even when the cells were treated with LPS at the time of infection (Day 0) or even 1 day later (Day ϩ1).
To evaluate the time-course of inhibition, monocyte-derived macrophages were cultured in the presence of 100 ng/ml LPS and infected with HIV-1 ADA or HIV-1 BaL . After 3, 5, 7, 9, and 12 days postinfection, culture supernatants were harvested and HIV-1 replication quantitated by p24 ELISA. After the supernatants were harvested, an equivalent volume of growth media containing 100 ng/ml LPS was added to each well to maintain the effective concentration of LPS throughout the experiment. LPS treatment of monocyte-derived macrophages suppressed HIV-1 replication effectively by Ͼ80% reduction in viral load as compared with the untreated cells for the entire duration of the experiment (Fig. 1B) .
To determine if the observed LPS-induced inhibition of viral replication was a result of blocking viral entry, we used realtime PCR to detect the level of viral transcripts synthesized after infection. Monocyte-derived macrophages were treated with LPS 4 h and 24 h before infection with HIV-1, at the time of infection, and 4 h after infection with HIV-1. The cells were harvested 24 h postinfection, and total RNA was isolated. The RNA samples were reverse-transcribed, and the resulting cDNA samples were subjected to real-time PCR to amplify the HIV-1 sequences. The results shown in Figure 2 indicate that 24 h pretreatment of macrophages with LPS substantially decreased the level of steady-state viral RNA. Furthermore, substantial inhibition of viral replication was observed even when the cells were treated with LPS at the time of infection and 4 h after infection. In addition, treatment of macrophages for 4 h with LPS before infection with HIV-1 was sufficient to decrease the level of steady-state viral RNA detected. These results indicate that LPS treatment not only inhibits the entry substantially but also inhibits post-entry events in the life cycle of HIV-1.
Effect of PKC inhibitor on LPS-induced inhibition of viral replication
LPS-induced inhibition of HIV-1 is likely to be mediated by the involvement of LPS-induced signaling events. LPS binds initially to the CD14 and TLRs at the cell surface and activates a number of signal transduction pathways including the MAPK pathway, the PI3K pathway, and the PKC pathway. The MAPK family of proteins includes the p38, p42/p44 ERK, and JNK, which serve as transducers of signals from the cell surface. To study the involvement of a specific signal transduction pathway involved in the LPS-mediated inhibition, macrophages were pretreated for 2 h with 20 M specific inhibitors of p38 MAPK (SB 202190 and SB 203580) and MAPK inhibitor control compound (SB 202474), inhibitor of p42/p44 ERK (PD 98059), JNK inhibitor (SP 600125), NF-B inhibitor (BAY 11-7082), 250 nM PKC inhibitor (Go6976), and 50 M PI3K inhibitor (LY294002), followed by incubation with LPS for 24 h. The cells were then infected with HIV-1, and total cell RNA was isolated 24 h postinfection. The RNA samples were reversetranscribed, and the resulting cDNA samples were subjected to semiquantitative and real-time PCR to amplify HIV-1 sequences. Semiquantitative and real-time PCR analysis of the cDNA synthesized from the RNA samples isolated from HIV-1-infected monocyte-derived macrophages, which were pretreated with the PKC inhibitor (Go6976), demonstrated considerable reversal of the inhibition of HIV-1 replication induced by LPS treatment (Fig. 3, A and B, respectively). Pretreatment with the PI3K inhibitor (LY294002) alone or NK-B inhibitor (BAY 11-7082) alone caused a down-regulation of HIV-1 replication, which was inhibited further by LPS treatment (Fig. 3 , A and C, respectively). In contrast, pretreatment with the ERK inhibitor (PD 98059), the p38 inhibitors (SB 202190 and SB 203580), or the JNK inhibitor (SP 600125) had no effect in reversing the inhibition of viral replication and was similar to the results obtained when the cells were pretreated with the control compound (SB 202474) or DMSO alone (Fig. 3 , C and D, respectively). In addition to PCR, the inhibition of viral replication was quantitated by p24 ELISA. Monocyte-derived macrophages were pretreated with 250 nM PKC inhibitor (Go6976), 50 M PI3K inhibitor (LY 294002), and 20 M-specific inhibitors of p38 MAPK (SB 202190 and SB 203580) and control compound SB 202474, inhibitor of p42/p44 ERK (PD 98059), JNK inhibitor (SP 600125), and NF-B inhibitor (BAY 11-7082) and then incubated with LPS for 24 h. After 24 h, monocyte-derived macrophages were infected with HIV-1. The culture supernatants were harvested after 5 days postinfection, and HIV-1 replication was quantitated by p24 ELISA. As shown in Figure 4 , A and B, respectively, treatment with LPS had a profound inhibitory effect on viral replication. Supernatants from cells that were treated with LPS demonstrated Ͼ90% reduction in viral load compared with the cells treated with control alone (SB 202474) or those treated with DMSO as vehicle alone (Fig. 4, A and B) . Pretreatment of cells with the PKC inhibitor (Go 6976) partially reversed the effect of LPS-induced down-regulation of viral replication (Fig. 4A) . However, the inhibitory effect of LPS on viral replication was not reversed with the pretreatment of cells with MAPK inhibitors (Fig. 4B) . As expected, the PI3K inhibitor, JNK inhibitor (SP 600125), and NF-B inhibitor (BAY 11-7082) by themselves inhibited viral replication (Fig. 4,  A and B, respectively) .
LPS treatment up-regulates HO-1 gene expression
LPS is known to induce HO-1 expression in monocytes. Semiquantitative and real-time PCR analysis of the cDNA, synthesized from the RNA samples, isolated from monocyte-derived macrophages, and treated with 100 ng/ml LPS demonstrated that LPS caused an up-regulation of HO-1 gene expression.
The induction of HO-1 gene expression could be detected as early as 4 h post-LPS treatment (Fig. 5, A and B, respectively). Pretreatment with the PKC inhibitor (Go6976) was able to inhibit the induction of HO-1 gene expression caused by LPS treatment (Fig. 5 , C and D, respectively), indicating that the up-regulation of HO-1 gene expression by LPS was mediated by a PKC-sensitive pathway.
Inhibition of HO-1 enzymatic activity reverses LPS-induced inhibition of viral transcription
To determine whether the inhibition of HO-1 activity would reverse the LPS-induced inhibition of HIV-1 replication, monocyte-derived macrophages were incubated with 10 M SnPP IX, an inhibitor of HO-1 activity, 2 h before treatment with 50 ng/ml LPS. Subsequently, the cells were infected with HIV-1, and total cell RNA was isolated 24 h postinfection. Semiquantitative and real-time PCR analysis of the cDNA synthesized from the RNA samples indicated that pretreatment with SnPP IX greatly attenuated the effect of LPS-induced down-regulation of HIV-1 replication (Fig. 6, A and B, respectively). Treatment of monocyte-derived macrophages with 10 mM SnPP IX alone had no effect on viral replication and was similar to that of control cells. Thus, these results indicate that functional activity of HO-1 was essential for the inhibitory effect of LPS on viral replication.
DISCUSSION
In the present report, we have shown that LPS suppresses HIV-1 replication in primary human monocytes by PKC-dependent HO-1 induction. To our knowledge, this is the first report describing a role of HO-1 in LPS-induced protection of monocytes against HIV infection. Binding of bacterial LPS to cell-surface receptors triggers the activation of multiple signal transduction pathways. Signal transduction events initiated by LPS can affect many of the downstream events that are crucial for HIV-1 replication [23, 24] . Stimulation of monocyte-derived macrophages by LPS leads to the activation of several transcription factors, includ- The cDNA derived from total cellular RNA isolated from HIV-1-infected monocyte-derived macrophages was subjected to realtime PCR using HIV-1-specific primers. Each experimental sample was normalized relative to the endogenous control and the relative amount of target gene quantitated and expressed as relative mRNA units. The data are representative of two independent experiments using monocytes isolated from two different donors. Results expressed as mean Ϯ sem are representative of two independent experiments. ***, P Ͻ 0.005; **, P Ͼ 0.1. P values indicate statistical significance of difference from control by one-way ANOVA with a Dunnett multiple comparisons.
ing NF-B and AP-1, which in turn, leads to the induction of a number of host factors, such as proinflammatory cytokines, ␤-chemokines, and host-protective factors [15] [16] [17] [18] [19] [20] [21] . One mechanism by which LPS can mediate the inhibitory effect on HIV-1 replication is by the production of ␤-chemokines MIP-1␣, MIP1-␤, and RANTES, which are the ligands for the coreceptor CCR-5. These ␤-chemokines can compete for the CCR-5 coreceptor and thus, down-regulate viral entry [25] [26] [27] . In addition, LPS has been shown to interfere directly with the expression of CCR-5 on the macrophage cell surface, leading to a decrease in coreceptor availability for viral attachment [28, 29] . Other studies have demonstrated that LPS treatment inhibits post-entry viral replication steps by inducing the degradation of the viral nucleoprotein complexes [33] . In spite of these and many other published reports, a clear understanding of how LPS mediated suppression of HIV-1 replication has remained unknown.
The results from this study show that treatment of monocyte-derived macrophages with LPS markedly inhibited HIV-1 replication, even when added 24 h postinfection. Furthermore, the inhibition of HIV-1 replication could be prolonged for a considerable period of time (12 days postinfection) with continuous LPS treatment. In spite of profound reduction of HIV-1 p24 detected in the culture supernatants of infected monocyte-derived macrophages pretreated with LPS, HIV-1 viral transcripts were still detectable by PCR. This suggests that although pretreatment with LPS could block viral entry substantially, it could not inhibit viral entry completely. The life cycle of the HIV-1 virus is complex, involving multiple viral and host-derived factors that act at different stages of the viral life cycle, resulting in a productive HIV-1 infection. Subsequent to viral entry, there are several steps in the HIV-1 life cycle, where the LPS-induced factor or factors can interact and inhibit HIV-1 infection. In fact, the profound inhibition of viral replication observed, even when the monocyte-derived macrophages were treated 24 h after productive infection with HIV-1, suggests that the factors induced by LPS treatment not only interfere with viral entry but also obstruct post-entry events. Therefore, the suppression of viral entry may not be the sole factor contributing to the observed LPS-mediated inhibition of HIV-1 infection.
The treatment of monocyte-derived macrophages with LPS stimulates multiple kinases involved in signal transduction pathways, resulting in the induction of many host factors [34] . In this study, we attempted to identify the kinase or kinases involved in the LPS-mediated inhibition of HIV-1 infection by 7082 ) and then exposed to LPS for 24 h. The cDNA samples were subjected to real-time and semiquantitative PCR using HIV-1 envspecific primers (A and C, upper panel) and GAPDH primers (A and C, lower panel). The PCR products were separated on a 2% agarose gel and stained with ethidium bromide. Each experimental sample subjected to real-time PCR amplification was normalized relative to the endogenous control and the relative amount of target gene quantitated and expressed as relative mRNA units. The data are representative of three independent experiments using monocytes isolated from three different donors. Results expressed as mean Ϯ sem are representative of three independent experiments. ***, P Ͻ 0.0002. P values indicate statistical significance of difference by one-way ANOVA comparing each pair using Student's t-test. using specific inhibitors of kinase pathways. Several studies have reported previously that the MAPK family of proteins, including the p38, p42/p44 ERK, and JNK, is induced by LPS treatment in monocytes [11] [12] [13] [14] [15] [16] . Furthermore, these kinases have been implicated in the LPS-induced production of TNF-␣ and other proinflammatory cytokines [35] . The results obtained from this study (Fig. 3, C and D, respectively) indicate that pretreatment with the ERK inhibitor (PD 98059) [36] or the p38 inhibitors (SB 202190 and SB 203580) [37] had no effect in reversing the LPS-induced inhibition of viral entry/ integration and transcription. Therefore, it is unlikely that these two pathways are involved in the LPS-induced suppression of HIV-1 replication. Although, previous reports have shown that the p38 MAPK inhibitor SB 203580 reversed the LPS-mediated suppression of HIV-1 replication [25] , we did not observe reversal of HIV-1 replication by PCR or p24 determination, when the monocyte-derived macrophages were pretreated with the p38 MAPK inhibitor SB 203580 and exposed to 100 ng/ml LPS (Figs. 3, C and D, and 4A, respectively) . The differences in these observations may be attributed to be a result of a higher concentration of LPS used. The transcriptional regulatory factors NF-B, c-Jun, and AP-1 are central participants in modulating the expression of many immunoregulatory factors that are involved in the inflammatory response associated with bacterial infection [18, 33] . The JNK inhibitor SP 600125 represses the transacting activity of c-Jun and suppresses AP-1 binding, blocking the induction of proinflammatory cytokines and other genes involved in LPS activation [38] . In a similar manner, the NF-B inhibitor BAY 11-7082 prevents the phosphorylation of NF-B, preventing gene activation [39] . Consistent with these facts, pretreatment of cells with the NK-B inhibitor (BAY 11-7082) or the JNK inhibitor (SP 600125) caused a partial reversal of the LPS-induced inhibition of viral entry/integration (Fig. 4B) , indicating that the JNK and NF-B pathways play a significant role in the LPSmediated inhibition of viral replication.
LPS treatment of monocytes also leads to the activation of PKC and the PI3K-Akt pathways [40 -42] . The PKC family of kinsases appears to be involved in the regulation of NF-Bdependent transcription by increasing the nuclear translocation of NF-B and up-regulating the phosphorylation of the NF-B subunit p65 [14] . Similarly, the PI3K-Akt pathway has been shown to regulate negatively many kinases that mediate the induction of proinflammatory genes and is implicated in monocyte survival and proliferation [43] . Therefore, we examined the role of these kinases in the LPS-mediated suppression of HIV-1 replication by treating monocyte-derived macrophages with the PKC inhibitor Go6976 and the PI3K inhibitor LY294002. The inhibitor Go6976 is a specific inhibitor for the PKC isoforms ␣ and ␤ [44] . Pretreatment with the PKC inhibitor (Go6976) could block the inhibition of HIV-1 entry/integration and reverse the inhibition of HIV-1 replication caused by LPS treatment (Figs. 3, A and B, and 4B, respectively) . However, pretreatment with the PI3K inhibitor (LY294002) and then exposed to 100 ng/ml LPS (E. coli strain 026:B6) for 24 h were subjected to p24 ELISA, according to the manufacturer's instructions. Culture supernatants were analyzed in triplicate. Results expressed as mean Ϯ sem are representative of two independent experiments using monocytes isolated from two different donors. ***, P Ͻ 0.0001; **, P Ͻ 0.0012; *, P Ͼ 0.05. P values indicate statistical significance of difference by one-way ANOVA comparing each pair using Student's t-test.
[45] had no effect in reversing the LPS-induced inhibition of viral entry/integration and replication, suggesting that PI3K does not play a significant role in the LPS-mediated inhibition of HIV-1 replication. Our data, therefore, indicate that the distinct intracellular signaling pathways leading to LPS-mediated inhibition of HIV-1 replication involve the PKC-␣/␤-dependent activation of the NF-B transcription factor.
LPS has been reported to induce the host factor, HO-1 expression in murine macrophages, alveolar cells, and human monocytes [20 -22, 46] . The induction of HO-1 may protect the cells from the harmful effects from LPS-mediated toxic shock [47] . Mice deficient in HO-1 expression exhibited a greater mortality rate as a result of endotoxic shock, and in other studies, overexpression of HO-1 could protect them from the detrimental effects of LPS treatment [48, 49] . In fact, the induction of the host-protective factor, HO-1 has been demonstrated to function as a cytoprotective agent in many stress-related and pathogenic conditions [50 -59] .
In addition to LPS, baicalin and other flavones are known to inhibit HIV-1 infection [60 -62] . These compounds also induce HO-1 expression [63] . HO-1 catalyzes the initial and rate-limiting step in the oxidative degradation of heme into biliverdin, free iron, and carbon monoxide [58] . The products of heme catabolism, bilirubin, and biliverdin have been demonstrated to inhibit HIV and SIV infection in vitro, presumably by inhibiting the protease activity and preventing viral entry [64, 65] . Although the exact mechanism is not known, the induction of HO-1, by virtue of its anti-inflammatory and antiapoptotic properties, together with the production of biliverdin and bilirubin, could function as a potent inhibitor of HIV-1 replication.
Recently, we have demonstrated a direct correlation between the hemin-induced expression of HO-1 and the suppression of HIV-1 replication [66] . In fact, induction of HO-1 activity in monocyte-derived macrophages by hemin could inhibit viral entry substantially and suppress HIV-1 replication completely, even when treated 24 h after infection. These results are analogous to the results obtained when monocytederived macrophages were treated with LPS. Furthermore, the treatment of monocyte-derived macrophages with LPS also induces the expression of HO-1 (Fig. 5, A and B, respectively) . The induction of HO-1 by LPS is mediated by the activation of PKC and the (NF-E2)-related transcription factor [67] . The LPS-mediated induction of HO-1 expression is modulated by the PKC inhibitor Go6976 (Fig. 5, C and D, respectively) . In Semiquantitative and real-time amplification of cDNA, derived from total cellular RNA, isolated from monocyte-derived macrophages, and treated with 100 ng/ml LPS (E. coli strain 026:B6) for the indicated times. (C and D) Semiquantitative and real-time amplification of cDNA, derived from total cellular RNA, isolated from monocyte-derived macrophages, and pretreated with 250 nM PKC inhibitor (Go6976) and then treated with 100 ng/ml LPS (E. coli strain 026:B6) for 6 h. The cDNA samples were subjected to semiquantitative PCR using HO-1-specific primers (A and C, upper) and GAPDH primers (A and C, lower). The PCR products were separated on a 2% agarose gel and stained with ethidium bromide. Each experimental sample subjected to real-time PCR amplification was normalized relative to the endogenous control and the relative amount of target gene quantitated and expressed as relative mRNA units. The data are representative of three independent experiments using monocytes isolated from three different donors. Results expressed as mean Ϯ sem are representative of three independent experiments. ***, P Ͻ 0.0004; **, P Ͻ 0.003; *, P Ͼ 0.1. P values indicate statistical significance of difference by one-way ANOVA comparing each pair using Student's t-test.
addition to suppressing HO-1, expression the PKC inhibitor Go 6976 also partially reversed the LPS-mediated inhibition of HIV-1 replication (Fig. 4A) . In addition, pretreatment of cells with SnPP IX, an inhibitor of HO-1 activity [68] , could substantially reverse the LPS-mediated inhibition of viral replication (Fig. 6, A and B, respectively) . Thus, taken together, these results indicate that HO-1 plays a critical role in the LPS-mediated inhibition of HIV-1 replication.
The HO family consists of three known isozymes, namely, the inducible HO-1 and the constitutively expressed HO-2 and HO-3 encoded by distinct genes [69, 70] . All three isozymes are involved in heme catabolism. SnPP IX is known to inhibit the enzyme activity of all three isozymes [70, 71] . The magnitude of the reversal of the LPS-mediated inhibition of viral replication, observed when the cells were pretreated with SnPP IX, was greater than that observed when the cells were pretreated with the PKC inhibitor Go6976. Pretreatment with the PKC inhibitor Go6976 inhibits the inducible HO-1 isozyme expression alone. In contrast, the pretreatment with SnPP IX inhibits all three isozymes of HO. Thus, the inhibition of all three isozymes by SnPP IX would result in a substantially greater reversal of the LPS-mediated inhibition of viral replication than that observed when only one isozyme is affected.
In summary, the data presented in this study demonstrate that the host defense factor HO-1 plays a pivotal role in the LPS-mediated down-regulation of HIV-1 replication and that the PKC signal transduction pathway mediates the downstream activation of genes that are involved in the LPS-mediated down-regulation of HIV-1 replication. These findings enhance our understanding of the mechanism involved in the LPS-mediated inhibition of viral infection and may provide guidance in developing future therapeutic interventions. AUTHORSHIP K. D. performed experiments; K. D., I. K. H., and S. D. contributed to designing research, analyzing data, discussing findings, and writing the manuscript.
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